Antiviral Drugs for EBV

Epstein–Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35–50% cases when infection occurs during adolescence and early adulthood....

Descripción completa

Detalles Bibliográficos
Autores principales: Pagano, Joseph S., Whitehurst, Christopher B., Andrei, Graciela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025560/
https://www.ncbi.nlm.nih.gov/pubmed/29899236
http://dx.doi.org/10.3390/cancers10060197
_version_ 1783336308308967424
author Pagano, Joseph S.
Whitehurst, Christopher B.
Andrei, Graciela
author_facet Pagano, Joseph S.
Whitehurst, Christopher B.
Andrei, Graciela
author_sort Pagano, Joseph S.
collection PubMed
description Epstein–Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35–50% cases when infection occurs during adolescence and early adulthood. Epstein–Barr virus is also associated with several B-cell malignancies including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease. A number of antiviral drugs have proven to be effective inhibitors of EBV replication, yet have resulted in limited success clinically, and none of them has been approved for treatment of EBV infections.
format Online
Article
Text
id pubmed-6025560
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60255602018-07-09 Antiviral Drugs for EBV Pagano, Joseph S. Whitehurst, Christopher B. Andrei, Graciela Cancers (Basel) Commentary Epstein–Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35–50% cases when infection occurs during adolescence and early adulthood. Epstein–Barr virus is also associated with several B-cell malignancies including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease. A number of antiviral drugs have proven to be effective inhibitors of EBV replication, yet have resulted in limited success clinically, and none of them has been approved for treatment of EBV infections. MDPI 2018-06-13 /pmc/articles/PMC6025560/ /pubmed/29899236 http://dx.doi.org/10.3390/cancers10060197 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Pagano, Joseph S.
Whitehurst, Christopher B.
Andrei, Graciela
Antiviral Drugs for EBV
title Antiviral Drugs for EBV
title_full Antiviral Drugs for EBV
title_fullStr Antiviral Drugs for EBV
title_full_unstemmed Antiviral Drugs for EBV
title_short Antiviral Drugs for EBV
title_sort antiviral drugs for ebv
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025560/
https://www.ncbi.nlm.nih.gov/pubmed/29899236
http://dx.doi.org/10.3390/cancers10060197
work_keys_str_mv AT paganojosephs antiviraldrugsforebv
AT whitehurstchristopherb antiviraldrugsforebv
AT andreigraciela antiviraldrugsforebv

Ejemplares similares